Continuing Medical Education


 

Instructions to Receive Credits
An email with the application link will be sent to all attendees to apply for CME/CE credits from the meeting post-conference. 

Target Audience
This activity is intended for physicians, nurses, and pharmacists engaged in the care of people with hemostatic and thrombotic disorders.

Educational Objectives
After completing this activity, the participant should be better able to:

Learning Objective for Pre-conference Session 1: “New Therapies”
At the close of this session, attendees will be able to:

  • Discuss new treatment options available to patients with bleeding and clotting disorders

  • Describe how new inhibitor treatments can affect laboratory test results

  • Analyze how treatment of bleeding and clotting disorders can be tailored using specific therapies

Learning Objective for Pre-conference Session 2: “Inclusive Care”
At the close of this session, attendees will be able to:

  • Explain the approach for gender-affirming medication treatment for gender dysphoria/incongruence

  • Describe the potential adverse reactions of estrogen/testosterone treatment and develop strategies to minimize risk

  • Explain the relationship between trauma, behavior, and health outcomes

  • Develop strategies that promote the implementation of trauma informed care in their practice

Learning Objectives for Scientific Session 1: “The Future of Hemophilia Therapeutics:  Substitution or Gene Therapy?” Debate
At the close of this session, attendees will be able to:

  • Explain the current state of development of gene therapy for hemophilia

  • Compare and contrast the advantages and disadvantages of protein replacement therapy and gene therapy

  • Describe the safety profiles of protein replacement therapy and gene therapy

Learning Objective for Scientific Session 2: State-of-the-Art Lecture and COVID-19
At the close of this session, attendees will be able to describe the current state of clinical, translational, and basic scientific studies investigating thrombotic and bleeding complications associated with SARS-CoV-2 infection.

Learning Objectives for Scientific Session 3-A: “Bench, Clinic, and Everything In-Between: Platelet Transfusion”
At the close of this session, attendees will be able to:

  • Describe platelet transfusion practices in the REDS-III pediatric cohort

  • Discuss whether the pathogen reduction process might impact antibody mediated platelet refractoriness

  • Analyze data from murine model to determine whether platelets can serve as adjuvants to recipient RBC alloantibody responses

Learning Objective for Scientific Session 3-B: “Bench, Clinic, and Everything In-Between: Sickle Cell-Associated Thrombosis”
At the close of this session, attendees will be able to describe ongoing clinical, translational, and biochemical studies investigating sickle-cell associate thrombosis.

Learning Objectives  for Scientific Session 3-C: “Bench, Clinic, and Everything In-Between: Post-Thrombotic Syndrome”
At the close of this session, attendees will be able to:

  • Explain the importance of the post-thrombotic syndrome (PTS) as a complication of deep venous thrombosis

  • Summarize risk factors and prevention and management strategies for PTS

  • Define and discuss the concept of post-pulmonary embolism syndrome

Learning Objective for Oral Abstract Sessions
At the close of these sessions, attendees will be able to discuss emerging topics and research in the field of hemostasis and thrombosis, based on submitted abstracts.

Learning Objective for Poster Presentation Sessions
At the close of these sessions, attendees will be able to discuss emerging topics and research in the field of hemostasis and thrombosis, based on submitted abstracts.

Faculty
List faculty, with complete titles and affiliations will be shared shortly, for now please refer to the program page.

Program Agenda
The program page includes the agenda and break times listed.

Joint Accreditation Statement

Jointly%20Accredited%20Provider%20TM

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and HTRS.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 10.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 10.5 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined. 

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 10.5  contact hour(s) (0.105CEUs) of the Accreditation Council for Pharmacy Education. 

(Universal Activity Number - JA4008162-9999-21-2464-L01-P) 

Type of Activity: Knowledge 

Hardware/Software Requirements
More information about hardware, software, internet connectivity and connection speed requirements for accessing the internet-based activity can be found on the general information page.

Policy on Privacy and Confidentiality 
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.  More information can be found on the general information page.

Interprofessional Continuing Education

IPCE%20Credit%20Logo_012017
This activity was planned by and for the healthcare team, and learners will receive 12.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Fee Information 
There is no fee for this educational activity.